Algernon Pharmaceuticals Inc. (AGN) (
CSE.AGN,
OTCQB:AGNPF, FRANKFURT: AGW,
Forum) – a Vancouver, BC-based clinical stage pharmaceutical development and drug repurposing company – has announced that the final patient has been enrolled in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from all countries participating in the study stands at 168.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, commented:
“I want to thank to the entire AGN team, including all of our clinical trial investigators and their staff, for helping us reach the goal of 100% patient enrollment. Our next big step is to see how the preliminary data is trending and we remain hopeful it will show that Ifenprodil is reducing both the severity and duration of a COVID-19 infection. Even with the recent success of certain vaccines in clinical trials, medical doctors need to have effective therapeutic treatment options as well.”
Full news release, click
here:
For more information on this Company, visit
algernonpharmaceuticals.com
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.